메뉴 건너뛰기




Volumn 12, Issue 4, 2012, Pages 464-470

Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AC 430; ADALIMUMAB; BARICITINIB; BMS 911543; CEP 33779; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR 1; CYTOKINE RECEPTOR 2; DASATINIB; GLPG 0634; IMATINIB; JANUS KINASE; JANUS KINASE INHIBITOR; METHOTREXATE; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NILOTINIB; PACRITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; R 348; R 723; RUXOLITINIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TOFACITINIB; UNCLASSIFIED DRUG; VX 509;

EID: 84864994569     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.008     Document Type: Review
Times cited : (193)

References (65)
  • 1
    • 82755186811 scopus 로고    scopus 로고
    • Cytokine signaling: Birth of a pathway
    • J.J. O'Shea, M. Gadina, and Y. Kanno Cytokine signaling: birth of a pathway J Immunol 187 2011 5475 5478
    • (2011) J Immunol , vol.187 , pp. 5475-5478
    • O'Shea, J.J.1    Gadina, M.2    Kanno, Y.3
  • 2
    • 0042932806 scopus 로고    scopus 로고
    • Molecular phylogeny within type i cytokines and their cognate receptors
    • J.L. Boulay, J.J. O'Shea, and W.E. Paul Molecular phylogeny within type I cytokines and their cognate receptors Immunity 19 2003 159 163
    • (2003) Immunity , vol.19 , pp. 159-163
    • Boulay, J.L.1    O'Shea, J.J.2    Paul, W.E.3
  • 3
    • 0031919849 scopus 로고    scopus 로고
    • Jaks and STATs: Biological implications
    • W.J. Leonard, and J.J. O'Shea Jaks and STATs: biological implications Annu Rev Immunol 16 1998 293 322
    • (1998) Annu Rev Immunol , vol.16 , pp. 293-322
    • Leonard, W.J.1    O'Shea, J.J.2
  • 4
    • 0028234529 scopus 로고
    • Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
    • J.E. Darnell Jr., I.M. Kerr, and G.R. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
    • (1994) Science , vol.264 , pp. 1415-1421
    • Darnell, Jr.J.E.1    Kerr, I.M.2    Stark, G.R.3
  • 5
    • 0036731485 scopus 로고    scopus 로고
    • Stats: Transcriptional control and biological impact
    • D.E. Levy, and J.E. Darnell Jr. Stats: transcriptional control and biological impact Nat Rev Mol Cell Biol 3 2002 651 662
    • (2002) Nat Rev Mol Cell Biol , vol.3 , pp. 651-662
    • Levy, D.E.1    Darnell, Jr.J.E.2
  • 6
    • 0026632288 scopus 로고
    • A protein tyrosine kinase in the interferon alpha/beta signaling pathway
    • L. Velazquez, M. Fellous, G.R. Stark, and S. Pellegrini A protein tyrosine kinase in the interferon alpha/beta signaling pathway Cell 70 1992 313 322
    • (1992) Cell , vol.70 , pp. 313-322
    • Velazquez, L.1    Fellous, M.2    Stark, G.R.3    Pellegrini, S.4
  • 7
    • 0027942119 scopus 로고
    • Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: Implications for X-linked severe combined immunodeficiency (XSCID)
    • W.J. Leonard, M. Noguchi, and S.M. Russell Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID) Adv Exp Med Biol 365 1994 225 232
    • (1994) Adv Exp Med Biol , vol.365 , pp. 225-232
    • Leonard, W.J.1    Noguchi, M.2    Russell, S.M.3
  • 11
    • 61849086101 scopus 로고    scopus 로고
    • Janus kinases in immune cell signaling
    • K. Ghoreschi, A. Laurence, and J.J. O'Shea Janus kinases in immune cell signaling Immunol Rev 228 2009 273 287
    • (2009) Immunol Rev , vol.228 , pp. 273-287
    • Ghoreschi, K.1    Laurence, A.2    O'Shea, J.J.3
  • 12
    • 0033987746 scopus 로고    scopus 로고
    • Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    • B.J. Druker, and N.B. Lydon Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3 7
    • (2000) J Clin Invest , vol.105 , pp. 3-7
    • Druker, B.J.1    Lydon, N.B.2
  • 13
    • 0033816156 scopus 로고    scopus 로고
    • Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
    • E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B.J. Druker, and N.B. Lydon Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 2000 139 145
    • (2000) J Pharmacol Exp Ther , vol.295 , pp. 139-145
    • Buchdunger, E.1    Cioffi, C.L.2    Law, N.3    Stover, D.4    Ohno-Jones, S.5    Druker, B.J.6    Lydon, N.B.7
  • 19
    • 77953218598 scopus 로고    scopus 로고
    • Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: A 'head-to-head comparison'
    • G. Rosti, F. Castagnetti, G. Gugliotta, F. Palandri, G. Martinelli, and M. Baccarani Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison' Leuk Lymphoma 51 2010 583 591
    • (2010) Leuk Lymphoma , vol.51 , pp. 583-591
    • Rosti, G.1    Castagnetti, F.2    Gugliotta, G.3    Palandri, F.4    Martinelli, G.5    Baccarani, M.6
  • 24
    • 39749164515 scopus 로고    scopus 로고
    • Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
    • A.J. Milici, E.M. Kudlacz, L. Audoly, S. Zwillich, and P. Changelian Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis Arthritis Res Ther 10 2008 R14
    • (2008) Arthritis Res Ther , vol.10 , pp. 14
    • Milici, A.J.1    Kudlacz, E.M.2    Audoly, L.3    Zwillich, S.4    Changelian, P.5
  • 26
    • 84857761516 scopus 로고    scopus 로고
    • Phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    • R. Fleischmann, M. Cutolo, M.C. Genovese, E.B. Lee, K.S. Kanik, S. Sadis, C.A. Connell, D. Gruben, S. Krishnaswami, G. Wallenstein, and B.E. Wilkinson Phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 2012 617 629
    • (2012) Arthritis Rheum , vol.64 , pp. 617-629
    • Fleischmann, R.1    Cutolo, M.2    Genovese, M.C.3    Lee, E.B.4    Kanik, K.S.5    Sadis, S.6    Connell, C.A.7    Gruben, D.8    Krishnaswami, S.9    Wallenstein, G.10    Wilkinson, B.E.11
  • 27
    • 84860388892 scopus 로고    scopus 로고
    • Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
    • Y. Tanaka, M. Suzuki, H. Nakamura, S. Toyoizumi, and S.H. Zwillich Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate Arthritis Care Res 63 2011 1150 1158
    • (2011) Arthritis Care Res , vol.63 , pp. 1150-1158
    • Tanaka, Y.1    Suzuki, M.2    Nakamura, H.3    Toyoizumi, S.4    Zwillich, S.H.5
  • 28
    • 81255159058 scopus 로고    scopus 로고
    • Targeting JAK3 in kidney transplantation: Current status and future options
    • D. Wojciechowski, and F. Vincenti Targeting JAK3 in kidney transplantation: current status and future options Curr Opin Organ Transplant 16 2011 614 619
    • (2011) Curr Opin Organ Transplant , vol.16 , pp. 614-619
    • Wojciechowski, D.1    Vincenti, F.2
  • 29
    • 84859265115 scopus 로고    scopus 로고
    • Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: Open label, long-term extension studies up to 36 months
    • J. Wollenhaupt, J.C. Silverfield, E.B. Lee, S. Wood, K. Soma, L. Wang, H. Nakamura, Y. Komuro, C.I. Nduaka, and D. Gruben Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: open label, long-term extension studies up to 36 months Arthritis Rheum 63 10 Suppl 2011 161 162
    • (2011) Arthritis Rheum , vol.63 , Issue.10 SUPPL. , pp. 161-162
    • Wollenhaupt, J.1    Silverfield, J.C.2    Lee, E.B.3    Wood, S.4    Soma, K.5    Wang, L.6    Nakamura, H.7    Komuro, Y.8    Nduaka, C.I.9    Gruben, D.10
  • 30
    • 80054118156 scopus 로고    scopus 로고
    • Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs
    • J. Kremer, Z-G. Li, S. Hall, R. Fleischmann, M. Genovese, E. Martin-Mola, J. Isaacs, D. Gruben, G. Wallenstein, and S. Krishnaswami Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs Ann Rheum Dis 70 Suppl 3 2011 170
    • (2011) Ann Rheum Dis , vol.70 , Issue.SUPPL. 3 , pp. 170
    • Kremer, J.1    Li, Z.-G.2    Hall, S.3    Fleischmann, R.4    Genovese, M.5    Martin-Mola, E.6    Isaacs, J.7    Gruben, D.8    Wallenstein, G.9    Krishnaswami, S.10
  • 31
    • 84866156845 scopus 로고    scopus 로고
    • A phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    • J.M. Kremer, S. Cohen, B.E. Wilkinson, C.A. Connell, J.L. French, J. Gomez-Reino, D. Gruben, K.S. Kanik, S. Krishnaswami, V. Pascual-Ramos, and G. Wallenstein A phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis Rheum 64 2012 970 981
    • (2012) Arthritis Rheum , vol.64 , pp. 970-981
    • Kremer, J.M.1    Cohen, S.2    Wilkinson, B.E.3    Connell, C.A.4    French, J.L.5    Gomez-Reino, J.6    Gruben, D.7    Kanik, K.S.8    Krishnaswami, S.9    Pascual-Ramos, V.10    Wallenstein, G.11
  • 32
    • 67650093218 scopus 로고    scopus 로고
    • The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
    • J.M. Kremer, B.J. Bloom, F.C. Breedveld, J.H. Coombs, M.P. Fletcher, D. Gruben, S. Krishnaswami, R. Burgos-Vargas, B. Wilkinson, C.A. Zerbini, and S.H. Zwillich The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum 60 2009 1895 1905
    • (2009) Arthritis Rheum , vol.60 , pp. 1895-1905
    • Kremer, J.M.1    Bloom, B.J.2    Breedveld, F.C.3    Coombs, J.H.4    Fletcher, M.P.5    Gruben, D.6    Krishnaswami, S.7    Burgos-Vargas, R.8    Wilkinson, B.9    Zerbini, C.A.10    Zwillich, S.H.11
  • 33
    • 84857718168 scopus 로고    scopus 로고
    • Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24-month phase 3 study
    • D. van der Heijde, Y. Tanaka, R. Fleischmann, E.C. Keystone, J.M. Kremer, C.A.F. Zerbini, M. Cardiel, S.B. Cohen, P.T. Nash, and Y.W. Song Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study Arthritis Rheum 2011 2592
    • (2011) Arthritis Rheum , pp. 2592
    • Van Der Heijde, D.1    Tanaka, Y.2    Fleischmann, R.3    Keystone, E.C.4    Kremer, J.M.5    Zerbini, C.A.F.6    Cardiel, M.7    Cohen, S.B.8    Nash, P.T.9    Song, Y.W.10
  • 34
    • 84857885925 scopus 로고    scopus 로고
    • Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: A 6-month phase 3 study
    • B.R. Burmester Gerd-Reudiger, C. Charles-Schoeman, J. Wollenhaupt, B. Zerbini, C.A.F. Benda, D. Gruben, G. Wallenstein, S. Krishnaswami, S.H. Zwillich, and T. Koncz Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a 6-month phase 3 study Arthritis Rheum 63 10 Suppl 2011 288
    • (2011) Arthritis Rheum , vol.63 , Issue.10 SUPPL. , pp. 288
    • Burmester Gerd-Reudiger, B.R.1    Charles-Schoeman, C.2    Wollenhaupt, J.3    Zerbini, B.4    Benda, C.A.F.5    Gruben, D.6    Wallenstein, G.7    Krishnaswami, S.8    Zwillich, S.H.9    Koncz, T.10
  • 35
    • 39149103052 scopus 로고    scopus 로고
    • The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
    • E. Kudlacz, M. Conklyn, C. Andresen, C. Whitney-Pickett, and P. Changelian The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia Eur J Pharmacol 582 2008 154 161
    • (2008) Eur J Pharmacol , vol.582 , pp. 154-161
    • Kudlacz, E.1    Conklyn, M.2    Andresen, C.3    Whitney-Pickett, C.4    Changelian, P.5
  • 36
    • 84857239335 scopus 로고    scopus 로고
    • The Jak inhibitor CP-690,550 (tofacitinib) inhibits tnf-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type i interferon
    • S. Rosengren, M. Corr, G.S. Firestein, and D.L. Boyle The Jak inhibitor CP-690,550 (tofacitinib) inhibits tnf-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type I interferon Ann Rheum Dis 71 2012 440 447
    • (2012) Ann Rheum Dis , vol.71 , pp. 440-447
    • Rosengren, S.1    Corr, M.2    Firestein, G.S.3    Boyle, D.L.4
  • 38
    • 10044296324 scopus 로고    scopus 로고
    • The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing
    • M. Conklyn, C. Andresen, P. Changelian, and E. Kudlacz The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing J Leukoc Biol 76 2004 1248 1255
    • (2004) J Leukoc Biol , vol.76 , pp. 1248-1255
    • Conklyn, M.1    Andresen, C.2    Changelian, P.3    Kudlacz, E.4
  • 42
    • 77953208379 scopus 로고    scopus 로고
    • Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    • R.A. Mesa Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis IDrugs 13 2010 394 403
    • (2010) IDrugs , vol.13 , pp. 394-403
    • Mesa, R.A.1
  • 43
    • 80051986566 scopus 로고    scopus 로고
    • A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis
    • M.W. Greenwald, R. Fidelus-Gort, R. Levy, J. Liang, K. Vaddi, W.V. William, and R. Newton A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis Arthritis Rheum 62 Suppl 10 2010 2172
    • (2010) Arthritis Rheum , vol.62 , Issue.SUPPL. 10 , pp. 2172
    • Greenwald, M.W.1    Fidelus-Gort, R.2    Levy, R.3    Liang, J.4    Vaddi, K.5    William, W.V.6    Newton, R.7
  • 44
    • 84859270131 scopus 로고    scopus 로고
    • Dose ranging study of VX-509, an oral selective Jak3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA)
    • G. Spencer-Green, F. Fan, B. Frankovic, X. Luo, T. Hoock, and N. Damjanov Dose ranging study of VX-509, an oral selective Jak3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) Arthritis Rheum 63 Suppl 10 2011 L3
    • (2011) Arthritis Rheum , vol.63 , Issue.SUPPL. 10 , pp. 3
    • Spencer-Green, G.1    Fan, F.2    Frankovic, B.3    Luo, X.4    Hoock, T.5    Damjanov, N.6
  • 47
    • 80051667225 scopus 로고    scopus 로고
    • JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
    • A. Tefferi, and A. Pardanani JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective Blood Rev 25 2011 229 237
    • (2011) Blood Rev , vol.25 , pp. 229-237
    • Tefferi, A.1    Pardanani, A.2
  • 52
    • 80054028202 scopus 로고    scopus 로고
    • Long-term outcome of treatment with ruxolitinib in myelofibrosis
    • A. Tefferi, M.R. Litzow, and A. Pardanani Long-term outcome of treatment with ruxolitinib in myelofibrosis N Engl J Med 365 2011 1455 1457
    • (2011) N Engl J Med , vol.365 , pp. 1455-1457
    • Tefferi, A.1    Litzow, M.R.2    Pardanani, A.3
  • 53
    • 79551575494 scopus 로고    scopus 로고
    • Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
    • A. Quintas-Cardama, H. Kantarjian, J. Cortes, and S. Verstovsek Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2011 127 140
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 127-140
    • Quintas-Cardama, A.1    Kantarjian, H.2    Cortes, J.3    Verstovsek, S.4
  • 62
    • 0029069540 scopus 로고
    • Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein
    • C.L. Yu, D.J. Meyer, G.S. Campbell, A.C. Larner, C. Carter-Su, J. Schwartz, and R. Jove Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein Science 269 1995 81 83
    • (1995) Science , vol.269 , pp. 81-83
    • Yu, C.L.1    Meyer, D.J.2    Campbell, G.S.3    Larner, A.C.4    Carter-Su, C.5    Schwartz, J.6    Jove, R.7
  • 63
    • 70350500225 scopus 로고    scopus 로고
    • STATs in cancer inflammation and immunity: A leading role for STAT3
    • H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
    • (2009) Nat Rev Cancer , vol.9 , pp. 798-809
    • Yu, H.1    Pardoll, D.2    Jove, R.3
  • 65
    • 77950833182 scopus 로고    scopus 로고
    • Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3
    • F. Yang, C. Brown, R. Buettner, M. Hedvat, R. Starr, A. Scuto, A. Schroeder, M. Jensen, and R. Jove Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 Mol Cancer Ther 9 2010 953 962
    • (2010) Mol Cancer Ther , vol.9 , pp. 953-962
    • Yang, F.1    Brown, C.2    Buettner, R.3    Hedvat, M.4    Starr, R.5    Scuto, A.6    Schroeder, A.7    Jensen, M.8    Jove, R.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.